Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014–2015 to 2016–2017 influenza seasons in Japan. Issue 6 (June 2018)

• Record Type: Journal Article
• Authors: Ishiguro, Nobuhisa; Koseki, Naoko; Kaiho, Miki; Ariga, Tadashi; Kikuta, Hideaki; Oba, Koji; Togashi, Takehiro; Morita, Keisuke; Inagawa, Akira; Okamura, Akiko; Yamazaki, Shigeru; Shida, Satoru; Konno, Mutsuko; Kawamura, Nobuaki; Ishizaka, Akihito; Takada, Kimihiko; Tsubakihara, Keiji; Nagano, Naoko; Shibata, Mutsuo; Furuyama, Hideto; Matsuzono, Yoshihiro; Koike, Akemi; Murashita, Mari; Hatae, Yoshio; Arioka, Hideki; Yamanaka, Tatsuru; Watanabe, Toru; Tabata, Yuuichi; Kumita, Yoshihiro; Hazama, Kyosuke; Akutsu, Yasushi; Aoyagi, Hayato; Tobise, Chie; Azuma, Katsuki; Yasoshima, Kohichi; Sawada, Yoko; Uetsuji, Kazuyuki; Tsuchida, Akira; Tsuchiyama, Akira; Yasuda, Kazue; Odagawa, Yasuhisa; Yoshioka, Mikio;
• Is Part Of: Journal of infection and chemotherapy. Volume 24:Issue 6(2018:Jun.)
• Page Start: 449
• Page End: 457
• Publication Date: 2018-06
• Subjects: Oseltamivir -- Zanamivir -- Laninamivir -- Peramivir -- Influenza A -- Influenza B; Chemotherapy -- Periodicals; Infection -- Periodicals; Communicable diseases -- Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1016/j.jiac.2018.01.013
• Languages: English
• ISSNs: 1341-321X

Abstract

Abstract: The clinical effectiveness of four neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, laninamivir, and peramivir) for children aged 0 months to 18 years with influenza A and B were investigated in the 2014–2015 to 2016–2017 influenza seasons in Japan. A total of 1207 patients (747 with influenza A and 460 with influenza B) were enrolled. The Cox proportional-hazards model using all of the patients showed that the duration of fever after administration of the first dose of the NAI was shorter in older patients (hazard ratio = 1.06 per 1 year of age, p < 0.001) and that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (hazard ratio = 2.21, p < 0.001). A logistic regression model showed that the number of biphasic fever episodes was 2.99-times greater for influenza B-infected patients than for influenza A-infected patients ( p < 0.001). The number of biphasic fever episodes in influenza A- or B-infected patients aged 0–4 years was 2.89-times greater than that in patients aged 10–18 years ( p = 0.010), and the number of episodes in influenza A- or B-infected patients aged 5–9 years was 2.13-times greater than that in patients aged 10–18 years ( p = 0.012).